Drug Profile


Alternative Names: Custirsen-sodium; ISIS 112989; OGX-011; TV-1011

Latest Information Update: 07 Dec 2016

Price : $50

At a glance

  • Originator University of British Columbia
  • Developer OncoGenex Pharmaceuticals
  • Class Antineoplastics; Antisense oligonucleotides; Thionucleotides
  • Mechanism of Action Clusterin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Non-small cell lung cancer; Prostate cancer
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Non-small cell lung cancer
  • Discontinued Breast cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 16 Nov 2016 Discontinued - Phase-I for Solid tumours (Combination therapy) in USA (IV)
  • 16 Nov 2016 Discontinued - Phase-III for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Ukraine, Thailand, Taiwan, Spain, Singapore, Russia, Poland, New Zealand, South Korea, Italy, Israel, Hungary, Germany, Australia, USA (IV)
  • 16 Nov 2016 Discontinued - Phase-III for Prostate cancer (Combination therapy, First-line therapy) in Canada, South Korea, South Korea, Spain, Netherlands, Italy, Israel, Hungary, Germany, France, Belgium, United Kingdom, USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top